GW Pharmaceutical Plc, which is developing cannabinoid medicines for epilepsy and other diseases of the central nervous system, reported a 20.1% decline in revenue to £8.2 million for the fiscal year ended 30 September 2017, while its operating loss soared by more than 70% to £153.3 million.
